4d pharma PLC (LSE:DDDD) - Share price


Stock Report

4d pharma PLC DDDD

Last Price
GBX100.94

Day Change
-3.46|-3.32%

As of 24/06/2021
15:13:28 BST | GBX
Minimum 15 Minutes Delay.

Last Close104.40p
Day Range100.00 - 103.40
Mkt Cap188.20Mil
52-Wk Range35.01 - 183.00
Yield %-
ISINGB00BJL5BR07
Volume521,855
P/E-
P/S2.27
P/CF-0.06

Share Price

Total Returns 23/06/2021

 Chg (%)  
More ...
4d pharma PLC7.63 
FTSE 100 TR GBP0.95
 
Financials
201820192020
More ...
Income Statement
Turnover0.000.210.51
Operating Profit-30.83-29.98-26.20
Net Profit-25.69-23.13-22.38
Reported EPS-39.40-35.08-19.81
Balance Sheet
Current Assets33.1611.2815.30
Non Current Assets19.4519.8620.73
Total Assets52.6131.1436.03
Current Liabilities5.184.956.24
Total Liabilities---
Total Equity45.7623.7928.60
Cash Flow
Operating Cash Flow-23.77-21.88-20.01
Net Change in Cash4.56-12.525.11
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
22/04/2021PurchaseDr. Alexander James Stevenson110.00658,840724,724.00
22/04/2021PurchaseMr. Duncan Joseph Peyton110.00658,840724,724.00
16/07/2020PurchaseDr. Alexander James Stevenson35.00571,428200,000.00
16/07/2020PurchaseDavid Robert Norwood35.00285,714100,000.00

Company Profile

4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

Sector

Biotechnology

Index

FTSE AIM All-Share

Next Event 30/09/2021

Half-Yearly Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-75.16
Op Mrgn-51.75
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Chief Scientific Officer and DirectorDr. Alexander James Stevenson
Chief Executive Officer and DirectorMr. Duncan Joseph Peyton
Non-Executive Chairman of the BoardProfessor Axel Gaston Glasmacher
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.